Sanofi (NASDAQ: SNY) has declared today that its BTK inhibitor, Rilzabrutinib, has been awarded Fast Track Designation from FDA. Rilzabrutinib has shown encouraging results in the Phase ½ study and now it is planning to commence Phase III study. Rilzabrutinib has the potential to treat
